Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Last trade$3.04
Day change-$0.57 (-15.79%)
Day range$3.01 – $3.71
Volume1,468,269
Market cap$385M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$385.17M
Price / earnings
—
Price / book
1.99×
Price / sales
—
EV / sales
—
EV / EBITDA
-5.59×
Profitability
Earnings per share
-$0.62
Return on assets
-32%
Return on equity
-33.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
26.37×
Quick ratio
26.37×
Cash ratio
0.74×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$51.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RLMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.88M
$6.62M
$11.37M
$12.26M
$6.29M
$7.4M
$6.27M
$8.08M
Research and development
$9.22M
$8.39M
$8.09M
$8.07M
$4.04M
$2.82M
$11.95M
$11M
Total operating expenses
$13.1M
$15.01M
$19.46M
$20.33M
$10.33M
$10.22M
$18.22M
$19.08M
Operating income
-$13.1M
-$15.01M
-$19.46M
-$20.33M
-$10.33M
-$10.22M
-$18.22M
-$19.08M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$13.86M
-$12.91M
-$19.05M
-$19.87M
-$10.09M
-$9.87M
-$17.56M
-$18.66M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$13.86M
-$12.91M
-$19.05M
-$19.87M
-$10.09M
-$9.87M
-$17.56M
-$18.66M
Net income attributable to common shareholders
-$13.86M
-$12.91M
-$19.05M
-$19.87M
-$10.09M
-$9.87M
-$17.56M
-$18.66M
EBITDA
-$13.1M
-$15.01M
-$19.46M
-$20.33M
-$10.33M
-$10.22M
-$18.22M
-$19.08M
Basic earnings per share
-$0.12
-$0.11
-$0.22
-$0.33
-$0.30
-$0.30
-$0.58
-$0.62
Diluted earnings per share
-$0.12
-$0.11
-$0.22
-$0.33
-$0.30
-$0.30
-$0.58
-$0.62
Recent news
Company coverage with links to the original publishers.
Relmada Therapeutics announced a conference call scheduled for November 12, 2026 at 4:30 PM ET to discuss third quarter 2026 financial results and business progress. The clinical-stage biotechnology company is advancing its lead candidates NDV-01 and sepranolone for oncology and central nervous system disorders, with NDV-01 progressing toward an IND filing expected by year-end 2026.
Relmada Therapeutics announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston (September 8-10, 2026). The company is advancing its lead candidates NDV-01 and sepranolone through clinical development, with NDV-01 expected to reach IND filing by year-end 2026 and a Phase 3 RESCUE registrational program planned for initiation.
Relmada Therapeutics, a clinical-stage biotechnology company, announced its addition to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026. The company's CEO attributed the achievement to robust 12-month data for its lead candidate NDV-01 in NMIBC treatment and a well-capitalized balance sheet.
Relmada Therapeutics announced presentations of NDV-01 clinical data at the American Urology Association conference in May 2026. Phase 2 data showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer patients. The company's Phase 3 'RESCUE' registrational program remains on track for mid-2026 initiation.
Relmada Therapeutics announced a conference call scheduled for March 19, 2026 at 4:30 PM ET to discuss fourth quarter 2025 financial results and business progress. The clinical-stage biotechnology company is also presenting at the Leerink Partners Global Healthcare Conference and recently completed an oversubscribed $160 million private placement financing.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.